About Menveo®

Like many parents of teens and preteens, you may not be aware that your child could catch meningococcal disease (including meningococcal meningitis) from normal, everyday activities, like sharing food, a water bottle, kissing—any activity where respiratory secretions, throat secretions, or saliva are exchanged.1

In fact, adolescents are at a higher risk for this rare, but deadly, illness. An illness that is so fast moving and hard to identify, that by the time it’s finally diagnosed, it could be too late.2 That’s why it’s so important to have your child vaccinated with Menveo.

Menveo, a meningococcal vaccine, is the latest  vaccine from Novartis Vaccines that helps provide important protection for your child against meningococcal disease.

Menveo has been shown to be safe and effective in preventing meningococcal disease and only 1 dose is required at time of vaccination.1,3


Indication

Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menveo is approved for use in persons 11 to 55 years of age. Menveo does not prevent N. meningitidis serogroup B infections.

Important Safety Information

You should not receive Menveo if you have had a severe allergic reaction to any ingredient of the vaccine, or if you have had a severe allergic reaction to a vaccine containing similar components as Menveo.

Side effects to Menveo include pain at the injection site, headache, muscle pain, fatigue, nausea, and fainting. Sometimes fainting is accompanied by falling with injury. Other side effects may occur.

Following vaccination with a US-licensed meningococcal conjugate vaccine, an evaluation of postmarketing adverse events suggested a potential for increased risk of Guillain-Barré Syndrome (GBS). There is not enough information to evaluate if a risk of GBS exists following administration of Menveo.

Tell your doctor if you are pregnant or planning to get pregnant.

Vaccination with Menveo may not protect all individuals.

For more information about Menveo, talk to your health-care professional.

Menveo.com has been developed by Novartis Vaccines as part of the company’s commitment to individual and public health.


References

  1. Meningococcal meningitis. World Health Organization Web site. http://www.who.int/mediacentre/factsheets/fs141/en/. Accessed March 3, 2010.
  2. Meningitis: Myths about meningococcal disease. National Foundation for Infectious Diseases Web site. http://www.nfid.org/meningitis/consumers_myths.html. Accessed March 3, 2010.
  3. Menveo [prescribing information]. Cambridge, MA: Novartis Vaccines and Diagnostics Inc; 2010.
  4. Meningitis: Meningococcal vaccination. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/meningitis/vaccine-info.html. Accessed March 3, 2010.

Menveo.com Exit Notice

You are now leaving the Menveo.com site and moving to an external website independently operated and not managed by Novartis Vaccines and Diagnostics Inc. Novartis assumes no responsibility for the site. If you do not wish to leave this site, click Cancel. Or, click OK to continue.

OKCancel